APHLX | VIVIX | APHLX / VIVIX | |
Total Expense Ratio | 0.84 | 0.04 | 2,100% |
Annual Report Gross Expense Ratio | 0.86 | 0.04 | 2,150% |
Fund Existence | 14 years | 27 years | - |
Gain YTD | 7.498 | 6.533 | 115% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 5000000 | 20% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 310M | 196B | 0% |
Annual Yield % from dividends | 1.41 | 2.19 | 65% |
Returns for 1 year | 4.01 | 7.91 | 51% |
Returns for 3 years | 11.16 | 25.93 | 43% |
Returns for 5 years | 27.47 | 68.54 | 40% |
Returns for 10 years | 29.97 | 114.61 | 26% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FSAAX | 16.99 | -0.02 | -0.12% |
Fidelity Advisor Asset Manager 60% A | |||
VIVIX | 70.31 | -0.09 | -0.13% |
Vanguard Value Index I | |||
PAXGX | 17.96 | -0.07 | -0.39% |
Impax Global Opportunities Investor | |||
GCLLX | 17.34 | -0.07 | -0.40% |
Goldman Sachs Enhanced U.S. Equity C | |||
RYVLX | 648.02 | -6.66 | -1.02% |
Rydex NASDAQ-100® 2x Strategy A |